Participated · Series D · Jul 2026

Drug Farm leverages proprietary platforms—IDInVivo+ (which integrates genetics and AI to identify and validate targets in living systems) and MedChem5 (used to advance first-in-class candidates)—to discover and progress drug candidates. The company is developing treatments across rare disease, cardiovascular, kidney, metabolic, autoimmune, and infectious disease indications. Its lead program, DF-003, is a first-in-class ALPK1 inhibitor that has shown clinical improvement in an ongoing Phase 1b study for ROSAH syndrome and is positioned to enter a Phase 3 trial; DF-003 has received multiple FDA designations including Fast Track and Orphan Drug. Another key program, DF-006, is an orally administered ALPK1 agonist immunomodulator that completed single and multiple ascending dose evaluations in healthy volunteers and in virologically suppressed HBeAg-negative chronic hepatitis B patients, showing encouraging anti-HBV activity. Drug Farm has entered a clinical collaboration with Xiamen Amoytop Biotech to develop DF-006 for hepatitis B and hepatocellular carcinoma. The recent $55 million Series D first closing provides capital to advance pivotal trials, global development, regulatory activities, and R&D expansion.

Led · Series A · Nov 2021

Cellenkos is a clinical-stage biotech based in Houston, Texas focused on developing transformative allogeneic Treg cell therapies to treat autoimmune and inflammatory disorders. Its proprietary CRANE™ platform generates tissue-directed, activated and enriched Treg cells that seek, localize, proliferate and resolve tissue inflammation. Lead products include CK0802, a lung-homing umbilical cord blood–derived Treg therapy for Acute Respiratory Distress Syndrome (ARDS), and CK0804, a bone marrow–homing allogeneic Treg subpopulation for myelofibrosis. The company’s cord blood–derived Treg therapeutic platform is licensed from the University of Texas MD Anderson Cancer Center. Cellenkos was founded by Simrit Parmar, MD of MD Anderson and Golden Meditech Holdings Limited and operates an in-house cGMP facility enabling large-scale manufacturing where multiple doses can be generated from a single umbilical cord blood unit. Its off-the-shelf allogeneic cell products are cryopreserved and available on-demand for infusion at the point of care. Proceeds from the financing will be used to further development of its Treg cell therapy platform.

Led · Series C · May 2021

Oculis is a helvetico-Icelandic biopharmaceutical company focused on creating innovative treatments for eye and neurological disorders. The firm is legally based in Zug with its operational headquarters in Lausanne. Its pipeline of ophthalmic therapies has attracted strong investor interest, reflected in two capital increases exceeding $100 million within a year. Management states that the newly secured funds will accelerate the clinical development of its drug candidates. The company positions itself as a leader in addressing unmet medical needs in ophthalmology through novel therapeutic approaches. Financially, Oculis has now raised at least $220 million across its last two rounds, underscoring sustained investor confidence. No revenue or user metrics were disclosed in the available article excerpt.

Participated · Series B · Jul 2019

BioNTech is a German biotech focused on mRNA vaccines and related therapeutics. The company is expanding its mRNA research and manufacturing footprint in Africa by enhancing its facility in Kigali, Rwanda. It will use CEPI funding to boost R&D capacity, support preclinical and clinical research by African researchers and organizations, and pursue vaccine development for HIV, malaria, and tuberculosis. BioNTech has agreed to dedicate up to half of the Rwanda facility's manufacturing capacity for public health emergencies and will seek regulatory authorization for the site. Financially, BioNTech reported Q1 2024 revenue of $202 million, down from nearly $1.38 billion in Q1 2023, and a Q1 net loss of $340 million (or $1.41 per share). The company has also pursued oncology partnerships as it adjusts to a post‑pandemic market. BioNTech develops individualized immunotherapies including mRNA-based product candidates, chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted antibodies and small molecules. Its pipeline comprises seven product candidates in eight ongoing clinical trials. The company has established a second GMP manufacturing license for production of its individualized neoantigen-specific immunotherapies and recently acquired a Phase I/IIa program from MabVax Therapeutics. BioNTech was founded in 2008 and is based in Mainz, Germany, and has also established a US research and development facility in San Diego. The company plans to use financing proceeds to advance its therapeutics pipeline and expand manufacturing infrastructure. Shareholders and investors include the Struengmann Family Office as majority shareholder and institutional investors such as Fidelity, Redmile, Invus, Janus Henderson and others. BioNTech develops precise and individualized immunotherapies, including individualized mRNA-based candidates, chimeric antigen receptors, T‑cell receptor compounds, checkpoint immunomodulators and small molecules. The company integrates diagnostics, drug development and manufacturing under one roof to accelerate programs. It describes itself as Europe’s largest privately‑held biopharmaceutical company and cites over 60 peer‑reviewed publications, including five in Nature. BioNTech extended its research collaboration with Sanofi, which has invested €80 million (approx. USD 91.5 million) in equity. The collaboration includes co‑development and co‑commercialization of a cancer immunotherapy candidate that is entering clinical testing in multiple solid tumors. The investigational therapy is an intratumorally injected mRNA mixture encoding immunomodulatory cytokines intended to stimulate innate and adaptive anti‑tumor immune responses while potentially reducing systemic toxicities. BioNTech is a biopharmaceutical company advancing individualized cancer immunotherapies. Its technologies include individualized mRNA-based medicines, chimeric antigen receptors, T-cell receptor-based products and novel checkpoint immunomodulators. The company plans to use new capital to advance its clinical pipeline across multiple approaches, including mRNA and CAR-T/T-cell receptor therapies for cancer and other diseases. BioNTech completed a $270M Series A financing to fund these efforts. Founded in 2008 and based in Mainz, Germany, the company has secured top-tier corporate partnerships with Genentech, Genmab, Eli Lilly, Sanofi and Bayer Animal Health. The Struengmann Family Office, an existing investor, participated in the Series A.

Participated · Convertible Note · Jun 2018

Stealth BioTherapeutics focuses on developing therapies that directly address mitochondrial bioenergetic deficits across rare and age-related diseases. The company’s development portfolio includes elamipretide programs in Barth syndrome, polymerase gamma–related mitochondrial disease and dry age-related macular degeneration, a next-generation clinical candidate bevemipretide for ophthalmic and neurological indications, and preclinical assets SBT-255 and SBT-589 for rare mitochondrial disorders. Its parent, Mighty Therapeutics, achieved FDA approval in September 2025 for the first commercial therapy for Barth syndrome and the first FDA-approved therapy to directly target mitochondria, generating revenue from its lead commercial product. The company plans to use newly secured capital to accelerate commercial launch activities and advance late-stage and pipeline development programs. Financially, current cash, cash equivalents and product revenues are expected to extend runway into 2028, with additional financing drawdowns projected to support cash flow positivity in early 2029.